The DC vaccine primes neoantigen-specific T cells, which then kill tumor cells presenting the cognate peptide–MHC complexes (mainly via MHC I) through perforin/granzyme or Fas–FasL pathways. HLA-DQB1 expression itself is not targeted for killing.